Compare iShares Self-Driving EV and Tech (IDRV) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Merck & Co., Inc. — how do they compare? iShares Self-Driving EV and Tech trades at $37.18, while Merck & Co., Inc. trades at $133.98 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while iShares Self-Driving EV and Tech pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.
| IDRV | MRK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $131.84 |
52-Week Low | $34.49 | $77.60 |
Market Cap | — | $321.77B |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $37.18, down 0.51% today, with a bullish technical signal from moving averages and key indicators like the ADX suggesting a strong trend. Support levels are firm near $35–$37, while resistance sits at $38–$39. Recent news highlights rising global EV sales, with growth in Europe and China, though U.S. adoption lags. The company has a dividend scheduled for June 2026.
The outlook for IDRV is cautiously optimistic, driven by sector tailwinds from EV adoption and regulatory support. Key risks include competitive pressures from Chinese automakers and sensitivity to fuel price volatility. Analyst sentiment is mixed, with technical strength offset by fundamental data gaps. Investors should monitor upcoming earnings for margin trends and guidance updates.
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
